Shannon Meeks
Pediatric Hematology-Oncology · Atlanta, GANPI 1275615502
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $90,584 and has fallen 95.3% since, to $4,250 in 2025. Among pediatric hematology-oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $1674.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioverativ Therapeutics Inc.$61K
- Spark Therapeutics, Inc.$42K
- Genentech USA, Inc.$37K
- Pfizer$34K
- Sanofi$20K
- Shire North American Group Inc$20K
- plus $40K from 8 others
Across 18 payments — averaging $962.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioverativ Therapeutics Inc.$10K
- Regeneron$5K
- Novo Nordisk AS$3K
What the payments were for
- Consulting fees$121,06148%
- Speaking & faculty fees$99,81539%
- Travel & lodging$30,80812%
- Food & beverage$2,8191%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bioverativ Therapeutics Inc. | 12 | $61,061 |
| Spark Therapeutics, Inc. | 43 | $42,305 |
| Genentech USA, Inc. | 25 | $37,207 |
| Pfizer | 18 | $34,295 |
| Sanofi | 11 | $20,170 |
| Shire North American Group Inc | 7 | $19,546 |
| CSL Behring | 9 | $13,420 |
| Novo Nordisk | 8 | $9,132 |
| Bayer | 12 | $8,115 |
| Genentech, Inc. | 1 | $4,620 |
| Biomarin Pharmaceutical Inc. | 2 | $3,508 |
| Octapharma USA, Inc. | 2 | $557 |
| F. Hoffmann-la Roche AG | 1 | $539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$254,548 in reported general payments places this provider in the 95th percentile of 74 pediatric hematology-oncology providers in Georgia.
See all pediatric hematology-oncology providers in Georgia →
Other pediatric hematology-oncology in Atlanta
- Robert SidonioAtlanta$834K
- Bhavya DoshiAtlanta$200K
- Muna QayedAtlanta$86K
- Shanmuganathan ChandrakasanAtlanta$67K
- Vivien SheehanAtlanta$51K
- Carlton DampierAtlanta$30K
- William CashAtlanta$28K
- Megan BrownAtlanta$24K
- Lakshmanan KrishnamurtiAtlanta$22K
- Carolyn BennettAtlanta$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.